Peptide Registry

P-21 (Adamantane)

$119.00

  • Contents: P-21 (Adamantane-DGGL; CNTF-derived tetrapeptide with adamantane modification)
  • Form: Lyophilized powder
  • Purity: >99%
Quantity Discount Price
1 - 3 - $119.00
4 - 7 10% $107.10
8 + 18% $97.58
SKU: N/A Category: Brand:

Description

P-21 is a synthetic neurotrophic peptide that Dr. Khalid Iqbal’s research team developed. Its core sequence, DGGL, corresponds to residues 147–150 of ciliary neurotrophic factor (CNTF). An adamantane moiety is attached to this tetrapeptide core. This modification increases lipid solubility and metabolic stability, enabling blood-brain barrier penetration that the bare CNTF-derived sequence lacks. P-21 is studied in nootropic peptide CNS research models for its effects on BDNF expression, dentate gyrus neurogenesis, and LIF/STAT3 pathway inhibition. Its mechanism was characterized in foundational preclinical work published by Li et al. in FEBS Letters (2010).

Chemical Information

  • Chemical Name: P-21 (Adamantane) (adamantane-modified analog related to the mitochondrial-derived peptide Humanin)
  • Also Known As: P-21; adamantane-conjugated Humanin analog
  • Compound Class: Modified synthetic peptide analog; adamantane-conjugated derivative within the Humanin/mitochondrial-derived peptide research family
  • Sequence: Not established in public literature as a single standardized sequence
  • Molecular Formula: Not established in public literature
  • Molecular Weight: Not established in public literature
  • CAS Number: Not established in public literature

Applications

  • Mitochondrial-derived peptide analog research. P-21 incorporates an adamantane group proposed to alter membrane permeability, receptor engagement, or proteolytic stability relative to unmodified Humanin. It is studied in the same general research context as Humanin, which signals through FPRL1/STAT3-linked cytoprotective pathways
  • Cytoprotection and cellular stress-resistance research. As with unmodified Humanin, researchers examine it in models of cellular stress resistance and apoptosis suppression, though the extent to which the adamantane modification changes potency or mechanism relative to native Humanin has not been independently established
  • Comparative Humanin analog research. Researchers use structurally modified Humanin analogs such as P-21 alongside unmodified Humanin to characterize how chemical modifications affect stability, cell permeability, and downstream signaling outcomes

Storage and Handling

Store lyophilized powder at -20C for long-term stability, or at 2-8C for short-term use. Protect from heat, moisture, and direct light. Reconstitute with sterile water or an appropriate aqueous buffer immediately before use; store reconstituted solution at 2-8C and avoid repeated freeze-thaw cycles.

Compliance Notice

P-21 (Adamantane) is for laboratory research use only. It is not for human or veterinary use and carries no therapeutic, diagnostic, or clinical indication. FDA has not evaluated this product. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.

Frequently Asked Questions

What is P-21?

P-21 is a synthetic tetrapeptide derived from residues 147–150 of ciliary neurotrophic factor (CNTF). It is modified with an adamantane moiety for blood-brain barrier penetration and metabolic stability. It is studied for LIF/STAT3 pathway inhibition, BDNF upregulation, dentate gyrus neurogenesis, and synaptic marker restoration in preclinical CNS models. All evidence is preclinical.

How does P-21's mechanism differ from Semax in BDNF research?

Both compounds produce BDNF upregulation as a downstream outcome in CNS research models. The upstream routes are different. Semax acts through ACTH-derived melanocortin receptor interaction to modulate TrkB pathway activity. P-21 first inhibits LIF/STAT3 signaling — removing an inhibitory constraint on neurogenesis — then drives BDNF expression as a downstream consequence. Researchers select between them based on whether the study requires receptor-mediated neurotrophic modulation or disinhibition-driven neurogenic environment research.

Why is the adamantane modification significant for P-21 research design?

The bare DGGL tetrapeptide core lacks sufficient lipid solubility and metabolic stability to reach CNS tissue at meaningful concentrations. The adamantane moiety solves both problems simultaneously — it increases membrane permeability for BBB crossing and provides resistance to enzymatic degradation in plasma. Without this modification, P-21's preclinical CNS findings would not be reproducible. Researchers should note that the adamantane component also affects the compound's molecular weight and analytical detection profile relative to unmodified tetrapeptides.